Verification of CiPA Recommended Voltage Protocols in Patch-Clamp Assay for hERG, Cav1.2 and Late Nav1.5 Currents
View file
As revising an ICH regulatory guideline, S7B, for the Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation by Human Pharmaceuticals) was suggested, Comprehensive In
vitro Proarrhythmia Assay (CiPA) activities are being implemented. The suggested S7B revision includes an assay of cardiac ion channels other than hERG, and CiPA-recommended voltage protocols for patch clamping was recently announced. We, Group 5 of the JSPS iSmart (investigation of in silico/in vitro model for arrhythmogenic risk prediction) play a role of wet-data collection. This time we have investigated the applicability of those protocols